Cyclosporin A Suppresses Replication of Hepatitis C Virus Genome in Cultured Hepatocytes

Hepatology

Volumn 38, Issue 5, 2003, Pages 1282-1288

  Watashi, Koichi ^b   Hijikata, Makoto ^b   Hosaka, Masahiro ^b   Yamaji, Masashi ^b   Shimotohno, Kunitada ^a  

^a KYOTO UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INTERFERON; RIBAVIRIN;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFECT; ENZYME ACTIVITY; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; INTERNAL RIBOSOME ENTRY SITE; LIVER CELL CULTURE; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPLICON; SIGNAL TRANSDUCTION; VIROGENESIS; VIRUS CARRIER; VIRUS GENOME; VIRUS REPLICATION;

EID: 0142182744     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50449     Document Type: Article

References (31)

1. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, Kuo G. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989;321:1494-1500.
2. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-362.
3. Liang TJ, Jeffers LJ, Reddy KR, De Medina M, Parker IT, Cheinquer H, Idrovo V, et al. Viral pathogenesis of hepatocellular carcinoma in the United States. HEPATOLOGY 1993;18:1326-1333.
4. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-1492.
5. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110-113.
6. Kishine H, Sugiyama K, Hijikata M, Kato N, Takahashi H, Noshi T, Nio Y, et al. Subgenomic replicon derived from a cell line infected with the hepatitis C virus. Biochem Biophys Res Commun 2002;293:993-999.
7. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology 2000;47:119-125.
8. Watashi K, Hijikata M, Marusawa H, Doi T, Shimotohno K. Cytoplasmic localization is important for transcription factor nuclear factor-kappa B activation by hepatitis C virus core protein through its amino terminal region. Virology 2001;286:391-402.
9. Takeuchi T, Katsume A, Tanaka T, Abe A, Inoue K, Tsukiyama-Kohara K, Kawaguchi R, et al. Real-time detection system for quantification of hepatitis C virus genome. Gastroenterology 1999;116:636-642.
10. Kato N, Ikeda M, Mizutani T, Sugiyama K, Noguchi M, Hirohashi S, Shimotohno K. Replication of hepatitis C virus in cultured non-neoplastic human hepatocytes. Jpn J Cancer Res 1996;87:787-792.
11. Ikeda M, Sugiyama K, Mizutani T, Tanaka T, Tanaka K, Sekihara H, Shimotohno K, et al. Human hepatocyte clonal cell lines that support persistent replication of hepatitis C virus. Virus Res 1998;56:157-167.
12. Kiani A, Rao A, Aramburu J. Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity 2000;12:359-372.
13. Kato N, Ikeda M, Sugiyama K, Mizutani T, Tanaka T, Shimotohno K. Hepatitis C virus population dynamics in human lymphocytes and hepatocytes infected in vitro. J Gen Virol 1998;79:1859-1869.
14. Ikeda M, Kato N, Mizutani T, Sugiyama K, Tanaka K, Shimotohno K. Analysis of the cell tropism of HCV by using in vitro HCV-infected human lymphocytes and hepatocytes. J Hepatol 1997;27:445-454.
15. Ikeda M, Sugiyama K, Mizutani T, Tanaka T, Tanaka K, Shimotohno K, Kato N. Hepatitis G virus replication in human cultured cells displaying susceptibility to hepatitis C virus infection. Biochem Biophys Res Commun 1997;235:505-508.
16. Kato N, Sugiyama Y, Namba K, Dansako H, Nakamura T, Takami M, Naka K, et al. Establishment of a hepatitis C virus subgenomic replicon derived from human hepatocytes infected in vitro. Biochem Biophys Res Commun 2003;306:756-766.
17. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001;14:778-809.
18. Steinkasserer A, Harrison R, Billich A, Hammerschmid F, Werner G, Wolff B, Peichl P, et al. Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 (HIV-1): interference with early and late events in HIV-1 replication. J Virol 1995;69:814-824.
19. Akiyama H, Yoshinaga H, Tanaka T, Hiruma K, Tanikawa S, Sakamaki H, Onozawa Y, et al. Effects of cyclosporin A on hepatitis C virus infection in bone martow transplant patients. Bone Marrow Transplantation Team. Bone Marrow Transplant 1997;20:993-995.
20. Fan FS, Tzeng CH, Hsiao KI, Hu ST, Liu WT, Chen PM. Withdrawal of immunosuppressive therapy in allogeneic bone marrow transplantation reactivates chronic viral hepatitis C. Bone Marrow Transplant 1991;8:417-420.
21. Kanamori H, Fukawa H, Maruta A, Harano H, Kodama F, Matsuzaki M, Miyashita H, et al. Case report: fulminant hepatitis C viral infection after allogeneic bone marrow transplantation. Am J Med Sci 1992;303:109-111.
22. Inoue K, Sekiyama K, Yamada M, Watanabe T, Yasuda H, Yoshiba M. Combined interferon a2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol 2003;38:567-572.
23. Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002;8:S19-S27.
24. Teixeira R, Papatheodoridis GV, Burroughs AK. Management of recurrent hepatitis C after liver transplantation. J Viral Hepat 2001;8:159-168.
25. Ghobrial RM, Colquhoun S, Rosen H, Hollis P, Ponthieux S, Pakrasi A, Farmer DG, et al. Retransplantation for recurrent hepatitis C following tacrolimus of cyclosporine immunosuppression. Transplant Proc 1998;30:1470-1471.
26. Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, Kolesnikov V et al. Severe of multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. HEPATOLOGY 1995;21:30-34.
27. Wainberg MA, Dascal A, Blain N, Fitz-Gibbon L, Boulerice F, Numazaki K, Tremblay M. The effect of cyclosporine A on infection of susceptible cells by human immunodeficiency virus type 1. Blood 1988;72:1904-1910.
28. Karpas A, Lowdell M, Jacobson SK, Hill F. Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506. Proc Natl Acad Sci U S A 1992;89:8351-8355.
29. Vahlne A, Larsson PA, Horal P, Ahlmen J, Svennerholm B, Gronowitz JS, Olofsson S. Inhibition of herpes simplex virus production in vitro by cyclosporin A. Arch Virol 1992;122:61-75.
30. Damaso CR, Keller SJ. Cyclosporin A inhibits vaccinia virus replication in vitro. Arch Virol 1994;134:303-319.
31. Huss R. Inhibition of cyclophilin function in HIV-1 infection by cyclosporin A. Immunol Today 1996;17:259-260.